Posted inHematology-Oncology news Transplantation
Ruxolitinib Improves Failure-Free and Overall Survival Versus Best Available Therapy in Steroid-Refractory Acute GVHD: Final 24‑Month REACH2 Analysis
The 24‑month final analysis of the phase III REACH2 trial shows ruxolitinib produced longer failure‑free survival, improved median overall and event‑free survival, and a longer duration of response versus best available therapy (BAT) in patients with steroid‑refractory acute GVHD.